AGRX | Agile Therapeutics, Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	1.5100 - 1.5100
52 Week Range	0.2000 - 2.6063
Beta	1.54
Implied Volatility	297.16%
IV Rank	32.67%
Day's Volume	10,366
Average Volume	169,397
Shares Outstanding	6,904,500
Market Cap	10,425,795
Sector	Healthcare
Industry	Drug Manufacturers - Specialty & Generic
IPO Date	2014-05-23

Valuation
Profitability
Growth
Health
P/E Ratio	-0.89
Forward P/E Ratio	N/A
EPS	-1.70
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	19
Country	USA
Website	AGRX

Agile Therapeutics Inc is a women's healthcare company to fulfill the unmet health needs of women. Its product candidates are designed to provide women with contraceptive options. The firm's initial product, Twirla, (levonorgestrel and ethinyl estradiol) transdermal system is a non-daily prescription contraceptive. Twirla is based on proprietary transdermal patch technology, called Skinfusion, which is designed to allow drug delivery through the skin.

AGRX's peers: AMRX, AQST, ASRT, AVDL, BFRI, CPIX, CYTH, DRRX, ZOM, ESPR, EVOK, GHSI, KMDA, PTPI, RDHL, RMTI, TXMD, SHPH

*Chart delayed

Analyzing fundamentals for AGRX we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is frighteningly weak. For more detailed analysis please see AGRX Fundamentals page.

Watching at AGRX technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on AGRX Technicals page.